Mithramycin (Mithramycin), Plicamycin (Plicamycin)

Mithramycin and Plicamycin are antibiotics that were previously used to treat certain types of malignant tumors. They prevent the growth of cancer cells. However, these drugs are currently used only to reduce elevated calcium levels in the blood.

Possible side effects when taking Mitramycin and Plicamycin:

1. Digestive disorders - nausea, vomiting, diarrhea.

2. Ulcerations in the mouth.

3. More serious side effects are nosebleeds and bloody vomiting.

Therefore, the use of these drugs should be monitored by a doctor in order to promptly identify and prevent possible complications. In general, Mithramycin and Plicamycin should be used with caution due to the risk of dangerous side effects.

Mithramycin and Plicamycin are antibiotics that were previously used to treat certain types of malignancies. They prevent the growth of malignant cells. However, at present these drugs are used only to reduce high levels of calcium ions in the blood.

The use of Mithramycin and Plicamycin may cause side effects such as digestive disorders and oral ulceration. More serious complications are also possible - nosebleeds and bloody vomiting. Therefore, the use of these antibiotics should be carefully monitored by a physician to minimize the risk of side effects. In general, today Mitramycin and Plicamycin are used only in cases where other methods of treating hypercalcemia are ineffective.

Mithramycin and Plicamycin are two antibiotics that are used to treat certain types of diseases. Both drugs are often used in oncology and prevent the appearance of cancer. However, the side effects of these medications are quite problematic and you need to be careful when using them. Let's talk about mithramycin and plicamycin in more detail.

Mithramycin (sometimes called Mitoxanthin, Mitran and M-37166) was first synthesized in 1958 and has since established itself in the field of cancer treatment. Typically, it is taken 5-25 mg per day depending on the goals of the specific disease. A month after the start of therapy, the cancer begins to decrease in size, but if the prognosis is poor, then long-term treatment is required. For example, the full course is approximately three months, and the initial stage of the disease is much easier to treat than a later and more advanced process. In addition, the improvement is not always total, so after the end of therapy the patient sometimes needs to remain under observation and periodically